Bionime (TPE:4737) ROE % Adjusted to Book Value: -8.99% (As of Dec. 2025)


TPE:4737 Bionime Corp TPE:4737
65 GF Score
Price NT$56.70
GF Value NT$58.89
Valuation Fairly Valued
! 7 Warning Signs
View Full Analysis

What is Bionime ROE % Adjusted to Book Value?

Bionime TPE:4737 +0.89% 65 ROE % Adjusted to Book Value is -8.99% as of Dec. 2025. GuruFocus rates TPE:4737 with a GF Score™ of 65/100 and a GF Value™ of NT$58.89 (Fairly Valued). The stock has 7 warning signs investors should review.

Bionime's ROE % for the quarter that ended in Dec. 2025 was -20.58%. Bionime's PB Ratio for the quarter that ended in Dec. 2025 was 2.29. Bionime's ROE % Adjusted to Book Value for the quarter that ended in Dec. 2025 was -8.99%.

Bionime ROE % Adjusted to Book Value Related Terms

Bionime ROE % Adjusted to Book Value Historical Data

* Premium members only.

The historical data trend for Bionime's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Bionime ROE % Adjusted to Book Value Chart

Bionime Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
ROE % Adjusted to Book Value
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.91 1.95 0.14 -3.13 -4.34

Bionime Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
ROE % Adjusted to Book Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -3.33 -1.33 -1.33 -5.64 -8.99

TPE:4737 vs ISRG, BDX, MDLN: ROE % Adjusted to Book Value Comparison

For the Medical Instruments & Supplies subindustry, Bionime's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Bionime ROE % Adjusted to Book Value vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Bionime's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where Bionime's ROE % Adjusted to Book Value falls into.


TPE:4737
65GF Score
Bionime Corp TPE:4737
ROE % Adjusted to Book Value is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Bionime ROE % Adjusted to Book Value Calculation

Bionime's ROE % Adjusted to Book Value for the fiscal year that ended in Dec. 2025 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=-9.95% / 2.29
=-4.34%

Bionime's ROE % Adjusted to Book Value for the quarter that ended in Dec. 2025 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=-20.58% / 2.29
=-8.99%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a ROE % Adjusted to Book Value of -8.99% mean?
Bionime (TPE:4737) has a ROE % Adjusted to Book Value of -8.99% as of Dec. 2025. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Bionime and its competitors.
Is Bionime's ROE % Adjusted to Book Value too high?
Bionime's current ROE % Adjusted to Book Value is -8.99%. Overall, Bionime has a GF Score™ of 65/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Bionime's ROE % Adjusted to Book Value compare to ISRG and BDX?
Bionime's ROE % Adjusted to Book Value of -8.99% can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % Adjusted to Book Value for a Medical Devices & Instruments company?
A good ROE % Adjusted to Book Value depends on the Medical Devices & Instruments industry context. However, ROE % Adjusted to Book Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % Adjusted to Book Value mean?
A high ROE % Adjusted to Book Value can signal that a stock is expensive relative to its fundamentals. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Bionime and its competitors. Bionime's current ROE % Adjusted to Book Value is -8.99%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bionime stock overvalued right now?
Based on GuruFocus' analysis, Bionime (TPE:4737) is currently considered Fairly Valued. The stock's GF Value™ is NT$58.89, compared to a current price of NT$56.70 — trading 3.7% below its estimated fair value. The current ROE % Adjusted to Book Value is -8.99%. Bionime's overall GF Score™ is 65/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % Adjusted to Book Value calculated?
ROE % Adjusted to Book Value is calculated from a company's financial statements. For Bionime (TPE:4737), the current ROE % Adjusted to Book Value is -8.99% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Bionime (TPE:4737) Overvalued in 2026?

Based on GuruFocus' analysis, Bionime stock appears to be undervalued. The current stock price of NT$56.70 is trading 3.7% below its estimated GF Value™ of NT$58.89. GuruFocus considers Bionime to be Fairly Valued.

Key valuation signals for TPE:4737:

  • ROE % Adjusted to Book Value: -8.99%
  • GF Value™: NT$58.89 vs. price of NT$56.70 (3.7% below fair value)
  • GF Score™: 65/100 with 7 warning signs

No single metric tells the full story. See the TPE:4737 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Bionime Business Description

Address No. 100, Daqing Street, Section 2, South District, Taichung, TWN, 40242
Bionime Corp is engaged in the manufacturing and selling of medical instruments, providing biotechnology services, examining pharmaceuticals, and selling precision instruments. The company's revenue is derived from the sale of blood glucose meters and test strips to domestic and foreign clients. Geographically, it operates in Algeria, China, Switzerland, the United States, Belarus, Egypt, the United Arab Emirates, and other countries, of which it derives the maximum revenue from Algeria.
65GF Score

Get the complete analysis for TPE:4737

ROE % Adjusted to Book Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$56.70
Price
NT$58.89
GF Value